These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 10983738)

  • 1. Clopidogrel: a review of its use in the prevention of atherothrombosis.
    Jarvis B; Simpson K
    Drugs; 2000 Aug; 60(2):347-77. PubMed ID: 10983738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    CAPRIE Steering Committee
    Lancet; 1996 Nov; 348(9038):1329-39. PubMed ID: 8918275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events.
    Harker LA; Boissel JP; Pilgrim AJ; Gent M
    Drug Saf; 1999 Oct; 21(4):325-35. PubMed ID: 10514023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.
    Savi P; Herbert JM
    Semin Thromb Hemost; 2005 Apr; 31(2):174-83. PubMed ID: 15852221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients.
    Hacke W
    Cerebrovasc Dis; 2002; 13 Suppl 1():22-6. PubMed ID: 11803184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)].
    Scheen AJ
    Rev Med Liege; 2001 Mar; 56(3):186-9. PubMed ID: 11338792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
    Greenhalgh J; Bagust A; Boland A; Martin Saborido C; Oyee J; Blundell M; Dundar Y; Dickson R; Proudlove C; Fisher M
    Health Technol Assess; 2011 Sep; 15(31):1-178. PubMed ID: 21888837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data.
    Diener HC; Bogousslavsky J; Brass LM; Cimminiello C; Csiba L; Kaste M; Leys D; Matias-Guiu J; Rupprecht HJ
    Cerebrovasc Dis; 2004; 17(2-3):253-61. PubMed ID: 14981346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
    Hankey GJ; Sudlow CL; Dunbabin DW
    Cochrane Database Syst Rev; 2000; (2):CD001246. PubMed ID: 10796426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events.
    Caro JJ; Migliaccio-Walle K
    Am J Med; 1999 Dec; 107(6):568-72. PubMed ID: 10625025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit of ADP receptor antagonists in atherothrombotic patients: new evidence.
    Bogousslavsky J
    Cerebrovasc Dis; 2001; 11 Suppl 2():5-10. PubMed ID: 11316916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet agents in the prevention of cardiovascular morbidity and mortality in older patients with vascular disease.
    Aronow WS
    Drugs Aging; 1999 Aug; 15(2):91-101. PubMed ID: 10495069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease.
    Montalescot G
    Clin Cardiol; 2000 Nov; 23 Suppl 6(Suppl 6):VI-18-22. PubMed ID: 11129682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
    Jones L; Griffin S; Palmer S; Main C; Orton V; Sculpher M; Sudlow C; Henderson R; Hawkins N; Riemsma R
    Health Technol Assess; 2004 Oct; 8(38):iii-iv, 1-196. PubMed ID: 15461876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence with antiplatelet therapy and ADP-receptor antagonists.
    Easton JD
    Cerebrovasc Dis; 2003; 16 Suppl 1():20-6. PubMed ID: 12698015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current oral antiplatelet agents to prevent atherothrombosis.
    Hankey GJ
    Cerebrovasc Dis; 2001; 11 Suppl 2():11-7. PubMed ID: 11316917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events.
    Creager MA
    Vasc Med; 1998; 3(3):257-60. PubMed ID: 9892520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clopidogrel for cerebrovascular prevention.
    Paciaroni M; Bogousslavsky J
    Cerebrovasc Dis; 1999; 9(5):253-60. PubMed ID: 10473907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet drugs in secondary prevention after acute myocardial infarction.
    Thizon-de-Gaulle I
    Rev Port Cardiol; 1998 Dec; 17(12):993-7. PubMed ID: 9973860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.
    Diener HC; Bogousslavsky J; Brass LM; Cimminiello C; Csiba L; Kaste M; Leys D; Matias-Guiu J; Rupprecht HJ;
    Lancet; 2004 Jul 24-30; 364(9431):331-7. PubMed ID: 15276392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.